Previous Close | 2.3700 |
Open | 2.4000 |
Bid | 2.4000 x 400 |
Ask | 2.4700 x 400 |
Day's Range | 2.3800 - 2.4400 |
52 Week Range | 2.3600 - 4.3000 |
Volume | |
Avg. Volume | 429,565 |
Market Cap | 240.98M |
Beta (5Y Monthly) | 1.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings Date | Apr 24, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARAY
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to
Accuray's (ARAY) solid product demand raises optimism about the stock.